Abiopharma

🔍 KING A BRENT (Executive)

Company: Performance Food Group Co (PFGC)

Report Date: 2026-08-18

Detailed Transactions and Holdings:

• Acquired 12,619 shares of Common Stock (Direct)
  Date: 2026-08-18 | Code: A | equity_swap_involved: false | shares_owned_after: 56,220.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 4,596 shares of Common Stock at $104.54 per share (Direct)
  Date: 2026-08-18 | Code: F | equity_swap_involved: false | shares_owned_after: 51,624.00 | transaction_form_type: 4
• Sold 1,529 shares of Common Stock at $104.64 per share (Direct)
  Date: 2026-08-18 | Code: S | equity_swap_involved: false | shares_owned_after: 50,095.00 | transaction_form_type: 4 | Footnotes: F2
• Acquired 6,697 shares of Common Stock (Direct)
  Date: 2026-08-18 | Code: A | equity_swap_involved: false | shares_owned_after: 56,792.00 | transaction_form_type: 4 | Footnotes: F3
• Sold 969 shares of Common Stock at $103.34 per share (Direct)
  Date: 2026-08-19 | Code: F | equity_swap_involved: false | shares_owned_after: 55,823.00 | transaction_form_type: 4

Footnotes:

• F1: Represents a grant of performance-based restricted stock under the 2015 Omnibus Incentive Plan that vested on the date the Human Capital and Compensation Committee of the Company certified the achievement of the applicable performance targets based on the extent to which the applicable performance goals, which are based on relative total shareholder return, were attained for the performance period of July 2, 2023, to June 27, 2026.
• F2: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan established by the reporting person on February 20, 2026.
• F3: Represents a grant of restricted stock that vests in three equal annual installments beginning on August 18, 2027.
• REMARKS: Executive Vice President, General Counsel and Secretary